PI Industries: Business Overview & Financial Analysis
PI Industries Limited is an Indian chemical and crop protection enterprise headquartered in Gurugram, Haryana. Promoted by the Singhal family, the company operates an integrated business model spanning Custom Synthesis and Manufacturing (CSM) exports, domestic agricultural inputs, and pharmaceutical Contract Research, Development, and Manufacturing Organization (CRDMO) services. Operating multi-product manufacturing plants in Gujarat and R&D centers in Rajasthan and Telangana, PI Industries collaborates with global life sciences companies across North America, Europe, Japan, and Latin America.
Business Segment Revenue Breakdown of PI Industries (FY26)
- Agchem Custom Synthesis & Manufacturing (CSM Exports) – 79.0%
- Domestic Agri-Brands (Crop Protection & Bio-nutrients) – 17.0%
- Pharma CRDMO (Contract Research, Dev & Mfg) – 4.0%
The CSM export division forms the primary earnings engine, manufacturing active ingredients and intermediates under long-term contracts for global life science innovator partners. The domestic agri-brands business markets insecticides, fungicides, herbicides, and biologicals across India, while the emerging pharma CRDMO vertical provides early-stage synthesis and API commercialization.
Geographic Revenue Mix of PI Industries (FY26)
- Export Markets Share – 80.0%
- India Domestic Market Share – 20.0%
- Primary International Destination Share – ~45.0% North America & Europe
- Secondary International Destination Share – ~35.0% Japan & Latin America
International exports generate four-fifths of total corporate sales revenue, driven by supply agreements with global agrochemical innovators. Domestic operations cover 20% of net turnover, supported by an extensive distribution network servicing major agricultural belts across India.
Product Portfolio & Crop Category Coverage of PI Industries (FY26)
- Insecticides Category Share – 40.0%
- Fungicides Category Share – 30.0%
- Herbicides Category Share – 20.0%
- Specialty Bio-nutrients & Biologicals Share – 10.0%
- Core Crop Focus – Rice, Cotton, Soybean, Wheat, Corn, Sugarcane, and Horticulture
The product portfolio addresses pest, weed, and disease management across cereal, fiber, and commercial cash crops. Specialty biologicals and in-licensed molecules provide high-margin growth, expanding the domestic brand catalog.
Manufacturing Infrastructure & R&D Scale of PI Industries (FY26)
- Active Manufacturing Complexes – 5 multi-product plants (Jambusar, Panoli, Ankleshwar)
- Research & Development Facilities – 2 state-of-the-art centers (Udaipur & Hyderabad)
- R&D Workforce Personnel – 700+ scientists and 200+ doctorates
- Global Patent Portfolio – 220+ patents granted
- Active Pipeline Projects – 70+ projects under development
Manufacturing plants in Gujarat operate high-capacity multi-product reactors under GLP and NABL compliance. R&D centers in Udaipur and Hyderabad drive process chemistry research, route innovation, and biological formulation discovery.
Pharma CRDMO Division Performance of PI Industries (FY26)
- Annual Division Revenue Growth – +40.0% YoY
- Operating EBITDA Loss Reduction – -68.0% YoY
- Active Clinical Stage Programs – 6 programs (Phase I / II / III)
- Targeted Segment Scale Goal – 2x to 3x revenue expansion over 3 to 4 years
The pharma CRDMO division delivered 40% top-line growth in FY26 while narrowing operating EBITDA losses by 68%. Strategic investments focus on onboarding late-stage clinical programs across active pharmaceutical intermediates and biopharma molecules.
Operational & Commercialization Metrics of PI Industries (FY26)
- New Agchem Export Commercializations – 5 new molecules introduced
- Domestic Agri-Brand Launches – 3 new formulations commercialized
- Commercialization Pipeline Target – 8 to 10 molecules per annum
- First Indigenous NCE Registration – "PIOXANILIPROLE" filed in India
Commercialization momentum maintained pace with five new CSM molecules exported and three domestic agri-brands launched. The registration filing for PIOXANILIPROLE marks the company's first indigenous New Chemical Entity (NCE) entry.
Latest Quarterly Financial Performance of PI Industries (Q4 FY26)
- Consolidated Revenue from Operations – Rs 1,565.00 crore (-12.0% YoY)
- Agchem Export Revenue – Down ~15.0% YoY
- Domestic Agri Business Revenue – Down ~9.0% YoY
- Consolidated Operating EBITDA – Rs 337.30 crore (-26.2% YoY)
- Operating EBITDA Margin – 21.6% (-440 bps YoY)
- Consolidated Net Profit After Tax (PAT) – Rs 200.20 crore (-39.0% YoY)
- Confirmed Order Book Value – $1.1–1.2 billion
Quarterly revenue dropped 12% year-on-year to Rs 1,565.00 crore in Q4 FY26 due to inventory destocking by overseas clients. Net profit declined 39% to Rs 200.20 crore, while the long-term CSM order book held firm at $1.1–1.2 billion.
Consolidated Annual Financial Performance of PI Industries (FY26)
- Full Year Revenue from Operations – Rs 6,713.70 crore (-16.0% YoY)
- Full Year Operating EBITDA – Rs 1,510.50 crore (-22.0% YoY)
- Full Year Net Profit After Tax (PAT) – Rs 1,320.80 crore (-20.0% YoY)
- Surplus Cash & Investment Reserves – Rs 3,426.50 crore
- Debt to Equity Ratio – 0.02x (Net Cash Positive)
- Working Capital Cycle – 139 days
Full-year operating revenue contracted 16% to Rs 6,713.70 crore in FY26 as global channel inventories adjusted. Net Profit After Tax reached Rs 1,320.80 crore, with balance sheet liquidity supported by Rs 3,426.50 crore in surplus cash reserves.
Capex Pipeline & Capacity Expansion Roadmap of PI Industries (FY27–FY28)
- Planned Capital Expenditure Outlay – Rs 600–700 crore per annum
- Multi-Product Plant (MPP) Additions – 2 new MPPs commissioning in Jambusar
- Biological R&D Facility Expansion – Scaling up dedicated center in Hyderabad
- Funding Method – 100% internal cash accruals (Net Cash Balance Sheet)
Capital expenditure outlays focus on commissioning two new multi-product manufacturing plants at the Jambusar complex. Biological R&D capacity in Hyderabad is being expanded to build a proprietary peptide and bio-input portfolio.
Management Commentary & Strategic Outlook of PI Industries (Q4 FY26)
- Agchem export order dispatches are projected to recover progressively through H1 FY27 as overseas channel inventories normalize.
- Operating EBITDA margins are guided to stabilize around the 22.0%–24.0% band through cost optimization and high-margin product mix.
- Pharma CRDMO business is targeted to achieve 2x to 3x revenue growth over the next 3 to 4 years and reach EBITDA breakeven.
- Commercialization targets remain focused on scaling 8 to 10 new molecules per year across CSM exports and domestic lines.
- First indigenous NCE molecule PIOXANILIPROLE registration will be commercialized in India following regulatory clearance.
- Biologicals and peptide solutions will be expanded in international markets including the UK, US, Brazil, and Mexico.
- Surplus cash reserves of Rs 3,426.50 crore will be deployed toward inorganic pharma CRDMO assets and specialty chemical acquisitions.
- Working capital days are targeted to compress back toward 110–120 days as export shipping schedules align.
Management expects global agrochemical demand to trough during H1 FY27, with earnings momentum returning in H2 FY27. Strategic capital allocation will prioritize scaling the pharma CRDMO business, expanding biological R&D, and commercializing new CSM molecules.
Want to filter out stocks using your own financial benchmarks? You can use the Stock Screener on Finology Ticker to identify and compare companies based on specific growth and efficiency metrics.
Sources & References
- PI Industries Limited Q4 & Full Year FY26 Consolidated Financial Disclosures (May 2026)
- PI Industries Limited Q4 FY26 Earnings Call Transcript & Presentation (May 2026)
- PI Industries Limited Q1 FY26 Investor Presentation & Concall Transcript (August 2025)
- BSE India & NSE Official Corporate Announcements for PI Industries Limited
- Ticker Finology PI Industries Page
Disclaimer
The information presented above on PI Industries Limited has been compiled from the company's Annual Reports, Investor Presentations, Earnings Call (Concall) Transcripts, official regulatory filings and the financial data available on Finology Ticker. Certain figures, classifications or comparisons may vary due to differences in accounting policies, reporting methodologies or subsequent restatements by the company. This content is intended solely for informational purposes and should not be considered as investment advice. Investors are advised to refer to the latest company filings and the updated financial data, ratios and disclosures available on this Finology Ticker PI Industries Limited page before making any investment decision. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.